GlassScriptPhysician profile
Narayana Swamy
NPI 1831446020
$3,873.71
in general payments reported to CMS, 2019-2025
43 companies · $963 in 2025
The $963 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $984 · 2020: $481 · 2021: $33.66 · 2022: $67.60 · 2023: $419 · 2024: $926 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,287 · Education: $19.69.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,287.47 |
| Education | $19.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $974.11 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $682.78 | 2019-2025 | Tavneos, Enbrel, Evenity |
| Glaxosmithkline, LLC. | $337.36 | 2019-2025 | Benlysta |
| Ucb, INC. | $162.62 | 2022-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $130.66 | 2019-2023 | Taltz |
| Regeneron Healthcare Solutions, INC. | $127.54 | 2019-2020 | |
| Pfizer INC. | $127.26 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $91.18 | 2019-2025 | |
| Philips North America LLC | $83.51 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $82.35 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.99 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $75.42 | 2024-2025 | Voquezna |
| Aurinia Pharma U.S., INC. | $68.07 | 2024 | Lupkynis |
| Advanced Respiratory, INC | $65.88 | 2019-2020 | |
| Celgene Corporation | $59.97 | 2019 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $47.39 | 2023-2025 | Entyvio, Gattex |
| Dexcom, INC. | $46.85 | 2024 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.81 | 2024-2025 | Xifaxan |
| Genzyme Corporation | $41.92 | 2019-2025 | |
| Janssen Biotech, INC. | $41.78 | 2020-2024 | Tremfya |
| Genentech USA, INC. | $38.14 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $36.19 | 2025 | Recorlev |
| Sandoz INC. | $30.51 | 2023-2024 | Hyrimoz |
| Actelion Pharmaceuticals US, INC. | $28.21 | 2020 | |
| Horizon Therapeutics Plc | $28.18 | 2023 | Krystexxa |
| Harmony Biosciences LLC | $27.71 | 2020 | |
| Beta Bionics, INC. | $24.57 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Jazz Pharmaceuticals INC. | $23.17 | 2019 | |
| Aimmune Therapeutics, INC. | $23.05 | 2024 | |
| Radius Health, INC. | $22.75 | 2019 | |
| Tandem Diabetes Care, INC. | $21.34 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Enterra Medical, INC. | $19.21 | 2024 | |
| Resmed Corp | $18.31 | 2020 | |
| Sanofi-Aventis U.S. LLC | $17.79 | 2024 | |
| Merck Sharp & Dohme LLC | $17.74 | 2024 | Zinplava, Dificid |
| E.R. Squibb & Sons, L.L.C. | $17.43 | 2019 | |
| Insulet Corporation | $16.77 | 2025 | Omnipod |
| Medtronic, INC. | $16.15 | 2023 | Minimed 780g |
| Novo Nordisk INC | $16.07 | 2021 | |
| Optinose US, INC. | $15.97 | 2020 | |
| Celltrion USA INC. | $15.05 | 2025 | Vegzelma |
| Electromed, INC. | $14.43 | 2019 | |
| Circassia INC. | $12.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narayana Swamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.